Clinical Trials Logo
  1. Home
  2. Sarcoma, Soft Tissue
  3. NCT04887298

Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases

Sarcoma,Soft Tissue Clinical Trial

Official title:
Phase 1B/2 Study Of Liposomal Annamycin (L-Annamycin) In Subjects With Previously Treated Soft-Tissue Sarcomas With Pulmonary Metastases

Clinical Trial Summary

This is a multi-center, open-label, single-arm study that in Phase 1b will determine the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) and safety of L-Annamycin and in Phase 2 will explore the efficacy of L- Annamycin as a single agent for the treatment of subjects with STS with lung metastases for which chemotherapy is considered appropriate.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04887298
Study type Interventional
Source Moleculin Biotech, Inc.
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date June 5, 2021
Completion date May 2024
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT06114004 - Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc) Phase 2
Completed NCT01949506 - (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas N/A
Recruiting NCT04595994 - Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma Phase 1
Recruiting NCT05235100 - Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma Phase 2
Completed NCT04991883 - Analysis of the Molecular Profile of the Mixofibrosarcoma of the Extremities
Recruiting NCT04122872 - GISAR German Interdisciplinary Sarcoma Registry
Recruiting NCT04910126 - Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma Phase 2
Recruiting NCT04219202 - Neoadjuvant Irradiation of Retroperitoneal Soft Tissue Sarcoma With Ions Retro-Ion N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT05886634 - A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma Phase 2
Recruiting NCT05167994 - Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma Phase 2
Recruiting NCT04673942 - A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors Phase 2
Recruiting NCT05813327 - Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma Phase 1/Phase 2
Recruiting NCT04172805 - Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma Phase 2
Active, not recruiting NCT03600649 - Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas Phase 1
Recruiting NCT05894018 - Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma Phase 2
Recruiting NCT06263231 - A Study to Investigate Efficacy & Safety of INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3) Phase 3
Completed NCT01985295 - Combined Modality Treatment of Sarcomas of the Extremities Phase 1
Recruiting NCT05614375 - Endoscopic Surgery in the Treatment of Soft Tissue Sarcoma in Nasal and Paranasal Sinus